Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

The FDA has com­plet­ed its man­u­fac­tur­ing in­spec­tion for tislelizum­ab and the ap­pli­ca­tion is mov­ing for­ward, No­var­tis’ part­ner BeiGene an­nounced Tues­day morn­ing at its R&D day

The companies from the selected drugs will have to sign an agreement with the Centers for Medicare & Medicaid Services to participate in drug price